Rethinking ovarian cancer: recommendations for improving outcomes
…, D Etemadmoghadam, M Friedlander… - Nature Reviews …, 2011 - nature.com
There have been major advances in our understanding of the cellular and molecular biology
of the human malignancies that are collectively referred to as ovarian cancer. At a recent …
of the human malignancies that are collectively referred to as ovarian cancer. At a recent …
Chemotherapy‐induced peripheral neurotoxicity: a critical analysis
… of 16 to 26 mg/m 2 and increasing in incidence until 40 to 45 mg/m 2 but with no dramatic …
at a cumulative dose of approximately 45 mg/m 2 , although following a longer duration of …
at a cumulative dose of approximately 45 mg/m 2 , although following a longer duration of …
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
…, S Kehoe, L Kumar, M Friedlander - … of Gynecology & …, 2021 - Wiley Online Library
In 2014, FIGO’s Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, T Huzarski, A Poveda, S Pignata, M Friedlander… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
…, T Caldes, A Jakubowska, J Simard, ML Friedlander… - Jama, 2017 - jamanetwork.com
… Dr Friedlander reports receipt of fees for advisory board membership from AstraZeneca and
Pfizer. Dr Goldgar reports holding patents and receipt of royalties from Myriad Genetics. No …
Pfizer. Dr Goldgar reports holding patents and receipt of royalties from Myriad Genetics. No …
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor,
induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial …
induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
…, JA Ledermann, M Buck, A Dean, ML Friedlander… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…
Transcriptome and genome sequencing uncovers functional variation in humans
Genome sequencing projects are discovering millions of genetic variants in humans, and
interpretation of their functional effects is essential for understanding the genetic basis of …
interpretation of their functional effects is essential for understanding the genetic basis of …
[HTML][HTML] Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
…, RK Schmutzler, MW Audeh, M Friedlander… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
… Tutt A Robson M Garber JE , etal: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept …
patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept …
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
MW Audeh, J Carmichael, RT Penson, M Friedlander… - The lancet, 2010 - thelancet.com
Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor
that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess …
that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess …